ENXTPA:IPNPharmaceuticals
How Investors May Respond To Ipsen (ENXTPA:IPN) Positive Long-Term IQIRVO Data in PBC Trial
Recently, Ipsen presented late-breaking data from the ELATIVE trial at the AASLD Liver Meeting 2025 in Washington, revealing that IQIRVO® showed sustained biochemical response, stabilization of fibrosis markers, and notable symptom improvements over more than three years in primary biliary cholangitis patients.
Further analysis indicated that IQIRVO may influence fatigue-related mitochondrial pathways, suggesting the treatment's potential long-term impact on disease progression and patient...